Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To determine factors that contribute to delayed diagnosis and treatment of MS patients. Additionally, the study aimed to evaluate the correlation between diagnostic and therapeutic delay and disease outcome.

Methods: The current cohort observational multicenter study was performed at neurology clinics in four cities in Egypt. In this study, 239 MS patients were enrolled. Multiple Sclerosis Severity Scale (MSSS) and Expanded Disability Status Scale (EDSS) were utilized to measure disease severity and disability, respectively. Lag times for diagnosis were calculated in months from the time of the first symptoms to the accurate diagnosis.

Results: The results revealed that multiple important variables had a negative impact on the timely diagnosis, including the clinical type, as PPMS had longer delayed diagnoses versus RRMS/SPMS (p < 0.001). Conversely, the occurrence of sensory symptoms at disease onset is linked to prolonged diagnostic delay (p < 0.001). Multivariate logistic regression showed that young age, PPMS, and sensory symptoms were independently associated with delay in MS diagnosis. Patients initially sought medical assistance from ophthalmologists and neurologists, resulting in a significantly more delay in diagnosis (p < 0.001). A statistically positive correlation exists between the time for diagnosis and deterioration of MS assessed by EDSS, MSSS, or PI (p < 0.001). In addition, logistic regression analysis demonstrated that EDSS at diagnosis, delayed diagnosis, and illness duration were independently linked to MS severity (p < 0.001).

Conclusion: Many factors prolong the duration of MS diagnosis, including the age at disease onset, the delay in being referred from other medical specialties, and the presence of sensory symptoms at disease onset. Furthermore, MS delayed diagnosis and treatment leads to high disease disability with poor functional outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406396PMC
http://dx.doi.org/10.1186/s12883-025-04172-xDOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
8
diagnosis treatment
8
multicenter study
8
sclerosis patients'
4
patients' journey
4
journey delay
4
diagnosis
4
delay diagnosis
4
treatment multicenter
4
study
4

Similar Publications

Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate the effects of various physical therapy interventions on fatigue and quality of life in patients with multiple sclerosis (MS) using a network meta-analysis of randomized controlled trials (RCTs).

Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Cochrane databases through April 1, 2025. Eligible RCTs compared different exercise interventions in MS patients, focusing on fatigue and quality of life outcomes.

View Article and Find Full Text PDF

High morbidity and mortality associated with human β-coronavirus (CoV) infection highlight the need to determine host responses to infection and develop anti-viral therapies. Gap junction intercellular communication (GJIC), particularly involving Connexin43 (Cx43), is vital for maintaining central nervous system (CNS) homeostasis, and disruption of GJIC is a well-documented pathogenic mechanism among β-coronaviruses. Specifically, murine β-coronavirus, mouse hepatitis virus (MHV-A59) inoculation in the mouse brain causes acute-stage CNS viral spread and chronic neuroinflammatory demyelination while causing pronounced downregulation of Cx43 at the acute stage, reflecting a critical role in CNS pathology.

View Article and Find Full Text PDF

Objective: The objective of this study was to compare the long-term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS).

Methods: Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from 5 other UC Medical Centers were analyzed.

View Article and Find Full Text PDF